Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort

NCT06107140 | Completed

• 1 other identifier: CHT/URC/2023/13
• Study Type: observational
• Target: 580
• Locations: 1 country
• Sites: 1

Brief Summary

HIV infection requires lifelong continuous antiretroviral (ARV) treatment. The efficacy of current ARV treatments makes it possible to propose strategies for reducing the cumulative exposure to ARVs, side effects and costs. And so improve the quality of life of people living with HIV (PLHIV). However, in the real world, less regular adherence to treatment, more heavily pre-treated patients and resistance to treatment make these dual therapies prescribed beyond the strict framework of clinical trials. This can lead to undesirable side effects. From the perspective of personalized medicine, it seems to be important to determine which patients are receiving dual ARV therapy, and which patients remain on it for a long time. Identifying prognostic factors would enable us to adapt therapeutic management.

Conditions

HIV Infections

Keywords

epidemiology

Outcome Measures

Primary Outcomes (1)

• therapeutic switch

  Proportion of patients switching from dual to triple therapy

  5 years

Interventions

dual therapy OTHER

The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients followed up in a referral center for the management of PLHIV who started dual antiretroviral therapy in the period from 2011 to 2023 and whose viral load was \< 50 copies/ml before initiation of dual therapy.

You may qualify if:

• hiv patient
• viral load \< 50copies/ml
• patient treated with dual therapy
• patients with hospital follow-up between 2011 and 2023

You may not qualify if:

• adults under legal protection
• underage

Sponsors & Collaborators

• Tourcoing Hospital: lead

Study Sites (1)

Centre Hospitalier DRON

Tourcoing, 59208, France

Location

MeSH Terms

Conditions

HIV Infections

Interventions

Dual Anti-Platelet Therapy

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Intervention Hierarchy (Ancestors)

Drug Therapy, Combination; Drug Therapy; Therapeutics

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 24, 2023
• First Posted: October 30, 2023
• Study Start: January 1, 2011
• Primary Completion: May 1, 2023
• Study Completion: May 1, 2023
• Last Updated: November 1, 2023

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)